Sign up
Pharma Capital
Market: TSX-V
52-week High/Low: C$3.25 / C$0.68
Sector: Medical Cannabis
Market Cap: C$177.24M

WeedMD Rx Inc. is a licensed producer of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). WeedMD operates a 26,000 square foot, scalable production facility in Aylmer, Ontario with four acres of property for future expansion. WeedMD is focused on providing consistent, quality medicine to the long-term care and assisted living markets in Canada...

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in WeedMD

WeedMD Snapshot

To enrich the lives of patients through a cannabis-focused integrative medicine approach.

The Facility: The company operates a 26,000 sq. ft. facility located on 4 acres of land in Alymer, Ontario, and has an option to acquire neighboring land that would allow the company to expand to over 220,000 sq. ft of production space. Expansion of the building and construction of an extraction facility will begin in Q2 2017.

Leveraging an Unmatched Experience in Long-Term Care: WeedMD will leverage its deep industry relationships and 100 years of collective experience within the long-term care industry to become the first producer to focus on the long-term care and senior living market, a rapidly growing segment (4x the broader population) with frequent and regular consumption. 

Near-Term Value-Generating Milestones and Catalysts: WeedMD has a number of value-generating licensing and business milestones in the near future that will significantly enhance the company's production capabilities, including:

  • Sale license for dried cannabis is expected in early Q2 2017
  • Going public and trading on the TSX Venture Exchange under the symbol "WMD" beginning April 27, 2017
  • Extracts production license expected in the summer of 2017, once WeedMD has built out its extracts lab
  • Expanding to 220,000 sq. ft. (from 26,000 sq. ft.) to be completed in the summer of 2017

The Medical Cannabis Market Opportunity: Currently at a run-rate of ~$300MM in annual sales, the Canadian medical cannabis market is expected to grow to $1.4B-$3.0B in annual sales by 2024, a 25%+ CAGR. Furthermore, the Canadian federal government recently tabled legislation that would legalize recreational cannabis sales with the expectation of sales beginning mid-2018. The legal recreational market could hit $5B-$10B at the retail level by 2024.

WeedMD's management team is comprised of highly focused professionals with diverse backgrounds, and has over 100 years of collective experience in public, senior management and ownership roles in the long-term care industry.

Michael Kraft  Chairman

  • 25 years experience in sales & marketing, business & corporate development and finance
  • Founder of Buckingham Group Limited, a privately-owned merchant bank providing capital formation strategy and financing to private and public emerging growth companies

Bruce Scully – Chief Executive Officer

  • 22 years senior management experience in the Long-Term Care industry for both the private and public companies
  • Led 15 large company Government regulated start-ups
  • Expert in management and Government Relations

Keith Merker  Chief Financial Officer

  • 15 years as a Finance Professional, holds the Chartered Financial Analyst designation
  • Extensive experience working with emerging growth public and private companies in corporate finance, accounting and operations

Dr. Luc C. Duchesne – Chief Scientific Officer

  • PhD in Plant Biochemistry, 85 peer-reviewed publications
  • 30 years experience with production and commercialization of natural products

WeedMD Rx Inc.
Email: [email protected]
250 Elm Street
Aylmer, ON. N5H 2M8

Toll-Free: 1-844-WEEDMD-6 (1-844-933-3636)
Toll-Free Fax: 1-844-WEEDMD-7 (1-844-933-3637)

View full WMD profile View Profile
View All

Market Reports Including WMD


Executive video interviews


© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.